POH04 Treatment of medically intractable SUNCT and SUNA with occipital nerve stimulation
ObjectivesTo report on the outcome and follow-up of 7 medically intractable SUNCT and SUNA patients treated with ONS.BackgroundSUNCT and SUNA are primary headaches characterised by repeated attacks of very severe headaches in association with cranial autonomic features that usually occur several tim...
Saved in:
Published in: | Journal of neurology, neurosurgery and psychiatry Vol. 81; no. 11; pp. e51 - e52 |
---|---|
Main Authors: | , , |
Format: | Journal Article |
Language: | English |
Published: |
London
BMJ Publishing Group Ltd
01-11-2010
BMJ Publishing Group LTD |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | ObjectivesTo report on the outcome and follow-up of 7 medically intractable SUNCT and SUNA patients treated with ONS.BackgroundSUNCT and SUNA are primary headaches characterised by repeated attacks of very severe headaches in association with cranial autonomic features that usually occur several times daily. They can be medically intractable, in which case neurally destructive or cranially invasive treatments can be offered. ONS offers a nondestructive and relatively low-risk surgical alternative.MethodsSeven medically intractable patients (6 SUNCT, 1 SUNA) had bilateral ONS implants. Data were collected retrospectively for demographics, diagnosis, previous treatments, ONS settings, preimplantation and postimplantation headache characteristics, patients' estimates of change in headaches and complications.ResultsAt a median follow-up of 24 months (range 4–29), four patients reported a substantial improvement (95–100%), one reported moderate benefit (50%), one patient reported a temporary marked benefit (50%) for 6 months followed by recurrence of headache at the pre-ONS baseline, and one failed to respond. The onset of the benefit was rapid (within 2 weeks) with attacks recurring rapidly when the stimulator was switched off or malfunctioned. One patient developed hemicrania continua 1 month after implantation and was successfully treated with indometacin.ConclusionONS appears to offer a safe treatment option, without significant morbidity, for medically intractable SUNCT and SUNA. |
---|---|
Bibliography: | ark:/67375/NVC-7G95P258-L ArticleID:jnnp226340.138 istex:1E3801A26C35881DA971291CC783F279F44471A2 local:jnnp;81/11/e51-d href:jnnp-81-e51-4.pdf |
ISSN: | 0022-3050 1468-330X |
DOI: | 10.1136/jnnp.2010.226340.138 |